Optical identification of X-ray source 1RXS J180431.1-273932 as a magnetic cataclysmic variable

The X-ray source 1RXS J180431.1-273932 has been proposed as a new member of the symbiotic X-ray binary (SyXB) class of systems, which are composed of a late-type giant that loses matter to an extremely compact object, most likely a neutron star. In this paper, we present an optical campaign of imaging plus spectroscopy on selected candidate counterparts of this object. We also reanalyzed the available archival X-ray data collected with XMM-Newton. We find that the brightest optical source inside the 90% X-ray positional error circle is spectroscopically identified as a magnetic cataclysmic variable (CV), most likely of intermediate polar type, through the detection of prominent Balmer, He I, He II, and Bowen blend emissions. On either spectroscopic or statistical grounds, we discard as counterparts of the X-ray source the other optical objects in the XMM-Newton error circle. A red giant star of spectral type M5 III is found lying just outside the X-ray position: we consider this latter object as a fore-/background one and likewise rule it out as a counterpart of 1RXS J180431.1-273932. The description of the X-ray spectrum of the source using a bremsstrahlung plus black-body model gives temperatures of around 40 keV and around 0.1 keV for these two components, respectively. We estimate a distance of about 450 pc and a 0.2-10 keV X-ray luminosity of about 1.7e32 erg/s for this system and, using the information obtained from the X-ray spectral analysis, a mass of about 0.8 solar masses for the accreting white dwarf (WD). We also confirm an X-ray periodicity of 494 s for this source, which we interpret as the spin period of the WD. In summary, 1RXS J180431.1-273932 is identified as a magnetic CV and its SyXB nature is excluded.Comment: 9 pages, 7 figures, 3 tables, accepted for publication on Astronomy & Astrophysics, main journal. Version 2 includes the A&A Language Editor's correction

INTEGRAL hard X-ray spectra of the cosmic X-ray background and Galactic ridge emission

We derive the spectra of the cosmic X-ray background (CXB) and of the Galactic ridge X-ray emission (GRXE) in the ~20-200 keV range from the data of the IBIS instrument aboard the INTEGRAL satellite obtained during the four dedicated Earth-occultation observations of early 2006. We analyse the modulation of the IBIS/ISGRI detector counts induced by the passage of the Earth through the field of view of the instrument. Unlike previous studies, we do not fix the spectral shape of the various contributions, but model instead their spatial distribution and derive for each of them the expected modulation of the detector counts. The spectra of the diffuse emission components are obtained by fitting the normalizations of the model lightcurves to the observed modulation in different energy bins. The obtained CXB spectrum is consistent with the historic HEAO-1 results and falls slightly below the spectrum derived with Swift/BAT. A 10% higher normalization of the CXB cannot be completely excluded, but it would imply an unrealistically high albedo of the Earth. The derived spectrum of the GRXE confirms the presence of a minimum around 80 keV with improved statistics and yields an estimate of ~0.6 M_Sun for the average mass of white dwarfs in the Galaxy. The analysis also provides updated normalizations for the spectra of the Earth's albedo and the cosmic-ray induced atmospheric emission.Comment: 13 pages, 13 figures, minor changes to text, A&A in pres

[3H]Adenine is a suitable radioligand for the labeling of G protein-coupled adenine receptors but shows high affinity to bacterial contaminations in buffer solutions

[3H]Adenine has previously been used to label the newly discovered G protein-coupled murine adenine receptors. Recent reports have questioned the suitability of [3H]adenine for adenine receptor binding studies because of curious results, e.g. high specific binding even in the absence of mammalian protein. In this study, we showed that specific [3H]adenine binding to various mammalian membrane preparations increased linearly with protein concentration. Furthermore, we found that Tris-buffer solutions typically used for radioligand binding studies (50 mM, pH 7.4) that have not been freshly prepared but stored at 4°C for some time may contain bacterial contaminations that exhibit high affinity binding for [3H]adenine. Specific binding is abolished by heating the contaminated buffer or filtering it through 0.2-μm filters. Three different, aerobic, gram-negative bacteria were isolated from a contaminated buffer solution and identified as Achromobacter xylosoxidans, A. denitrificans, and Acinetobacter lwoffii. A. xylosoxidans, a common bacterium that can cause nosocomial infections, showed a particularly high affinity for [3H]adenine in the low nanomolar range. Structure–activity relationships revealed that hypoxanthine also bound with high affinity to A. xylosoxidans, whereas other nucleobases (uracil, xanthine) and nucleosides (adenosine, uridine) did not. The nature of the labeled site in bacteria is not known, but preliminary results indicate that it may be a high-affinity purine transporter. We conclude that [3H]adenine is a well-suitable radioligand for adenine receptor binding studies but that bacterial contamination of the employed buffer solutions must be avoided

Differential Inhibitory Effects of CysLT1 Receptor Antagonists on P2Y6 Receptor-Mediated Signaling and Ion Transport in Human Bronchial Epithelia

BACKGROUND: Cysteinyl leukotriene (CysLT) is one of the proinflammatory mediators released by the bronchi during inflammation. CysLTs exert their biological effects via specific G-protein-coupled receptors. CysLT(1) receptor antagonists are available for clinical use for the treatment of asthma. Recently, crosstalk between CysLT(1) and P2Y(6) receptors has been delineated. P2Y receptors are expressed in apical and/or basolateral membranes of virtually all polarized epithelia to control the transport of fluid and electrolytes. Previous research suggests that CysLT(1) receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. However, the detailed molecular mechanism underlying the inhibition remains unresolved. METHODOLOGY/PRINCIPAL FINDINGS: In this study, western blot analysis confirmed that both CysLT(1) and P2Y(6) receptors were expressed in the human bronchial epithelial cell line 16HBE14o-. All three CysLT(1) antagonists inhibited the uridine diphosphate (UDP)-evoked I(SC), but only montelukast inhibited the UDP-evoked [Ca(2+)](i) increase. In the presence of forskolin or 8-bromoadenosine 3'5' cyclic monophosphate (8-Br-cAMP), the UDP-induced I(SC) was potentiated but was reduced by pranlukast and zafirlukast but not montelukast. Pranlukast inhibited the UDP-evoked I(SC) potentiated by an Epac activator, 8-(4-Chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate (8-CPT-2'-O-Me-cAMP), while montelukast and zafirlukast had no such effect. Pranlukast inhibited the real-time increase in cAMP changes activated by 8-CPT-2'-O-Me-cAMP as monitored by fluorescence resonance energy transfer imaging. Zafirlukast inhibited the UDP-induced I(SC) potentiated by N(6)-Phenyladenosine-3',5'-cyclic monophosphorothioate, Sp-isomer (Sp-6-Phe-cAMP; a PKA activator) and UDP-activated PKA activity. CONCLUSIONS/SIGNIFICANCE: In summary, our data strongly suggest for the first time that in human airway epithelia, the three specific CysLT(1) receptor antagonists exert differential inhibitory effects on P2Y(6) receptor-coupled Ca(2+) signaling pathways and the potentiating effect on I(SC) mediated by cAMP and Epac, leading to the modulation of ion transport activities across the epithelia

Development of selective agonists and antagonists of P2Y receptors

Although elucidation of the medicinal chemistry of agonists and antagonists of the P2Y receptors has lagged behind that of many other members of group A G protein-coupled receptors, detailed qualitative and quantitative structure–activity relationships (SARs) were recently constructed for several of the subtypes. Agonists selective for P2Y1, P2Y2, and P2Y6 receptors and nucleotide antagonists selective for P2Y1 and P2Y12 receptors are now known. Selective nonnucleotide antagonists were reported for P2Y1, P2Y2, P2Y6, P2Y11, P2Y12, and P2Y13 receptors. At the P2Y1 and P2Y12 receptors, nucleotide agonists (5′-diphosphate derivatives) were converted into antagonists of nanomolar affinity by altering the phosphate moieties, with a focus particularly on the ribose conformation and substitution pattern. Nucleotide analogues with conformationally constrained ribose-like rings were introduced as selective receptor probes for P2Y1 and P2Y6 receptors. Screening chemically diverse compound libraries has begun to yield new lead compounds for the development of P2Y receptor antagonists, such as competitive P2Y12 receptor antagonists with antithrombotic activity. Selective agonists for the P2Y4, P2Y11, and P2Y13 receptors and selective antagonists for P2Y4 and P2Y14 receptors have not yet been identified. The P2Y14 receptor appears to be the most restrictive of the class with respect to modification of the nucleobase, ribose, and phosphate moieties. The continuing process of ligand design for the P2Y receptors will aid in the identification of new clinical targets